Opinion|Videos|February 19, 2024
Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life
Author(s)Rana R. McKay, MD, Neal Shore, MD, FACS
Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
China's NMPA Approves Pirtobrutinib Across CLL
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5